RIGLRigel Pharmaceuticals Inc. (New) — stock analysis & sentiment

At $36.81, RIGL sits roughly in the upper-middle of a wide 52-week band that runs from $21.81 to $52.24. The stock is about 69% above the low and roughly 30% below the high, and a range that spans more than a doubling from bottom to top points to a year of large swings rather than a steady drift. The beta of 1.13 says those moves have been only modestly amplified relative to the broad market, so much of that travel has come from company- and sector-specific news rather than market direction alone.

The market values the business at about $681 million, or roughly 1.7 times book value. The valuation multiples pull in different directions: a trailing P/E near 1.9 sits against a forward P/E of about 7.6, a gap that usually reflects trailing earnings inflated by items that are not expected to repeat. The reported profit margin above 100% is consistent with that reading, since net income exceeding revenue points to gains recognized outside of ordinary operations, such as tax or one-time items, rather than an operating result. Underlying revenue growth of about 10% is the more conventional figure in the set, and the forward multiple is what the market appears to be pricing against.

The recent news flow is mostly company-specific and centers on commercial and partnership developments. The two most recent items concern vepdegestrant — a breast cancer collaboration with Arvinas and Pfizer reported in May 2026, followed in July 2026 by the naming of a national specialty pharmacy partner for VEPPANU — which points to an expansion beyond the existing hematology and oncology franchise. Earlier coverage includes a quarterly report noting a 176% jump in revenue and a regulatory approval for TAVALISSE in Mexico through a partner. Only one item, an industry pipeline report on T-cell lymphoma, is sector-level background rather than news about the company itself.